Antivirals and other drugs for early-stage illness could ideally prevent hospitalizations, shorten the duration of infectiousness and limit long-term complications from COVID. As of this writing, only two therapies for early COVID are available, and both of them come with major logistical challenges. At that point, treatment shifts toward drugs for severe COVID, such as dexamethasone, which ideally keep the inflammation in check. In an interview with Scientific American, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, described the desired characteristics of early COVID treatments. Fluvoxamine, a pill used for treating anxiety disorders, shows some promise in treating early COVID.